Acute Bacterial Sinusitis
Conditions
Keywords
Moxifloxacin, MXF, Avelox, Sinusitis, Acute bacterial sinusitis, ABS
Brief summary
For each patient, an initial visit and at least one follow-up visit at the end of treatment should be documented by the treating physician in the case report form.
Interventions
Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Any patient with a diagnosis of acute bacterial sinusitis treated with Avelox® - in accordance with the local production information.
Exclusion criteria
* Those specified in the local product information - contraindications and precautions must be considered.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of potential benefits of an antibacterial therapy with Avelox® (moxifloxacin) in patients with acute bacterial sinusitis to whom this treatment was prescribed. Especially the time to improvement and resolution of clinical signs and symptoms of | Documentation at baseline and at at least one follow-up visit. Evaluation of therapy outcome at last follow-up visit at end of therapy (approximately after 7 days). |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of tolerability and safety of Avalox® in daily practice were investigated. | Evaluation of therapy outcome at last follow-up visit at end of therapy (approximately after 7 days). |
| Patient characteristics in acute bacterial sinusitis | Documentation at baseline visit. |
| History and frequency of sinusitis episodes | Documentation at baseline visit. |
| Diagnostic procedures and therapeutic options chosen by physicians in daily practice | Documentation at baseline visit. |
Countries
Austria, Bahrain, China, Egypt, France, Germany, Indonesia, Jordan, Kuwait, Lebanon, Malaysia, Netherlands, Pakistan, Philippines, Romania, Saudi Arabia, Singapore, United Arab Emirates, Yemen
Outcome results
None listed